Navigation Links
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Date:9/25/2007

Lilly Studies Predictive Factors to Better Target Patients for ALIMTA(R) (pemetrexed for injection) in the Treatment of Non-Small Cell Lung Cancer

BARCELONA, Spain, Sept. 25 /PRNewswire-FirstCall/ -- In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA(R) (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel. The data (ECCO Abstract # 6521)(1) were presented at the 14th European Cancer Conference (ECCO) in Barcelona. ALIMTA, manufactured and marketed by Eli Lilly and Company, is currently indicated for the second-line treatment of advanced NSCLC in more than 85 countries.

The retrospective analysis of Phase III data(2) consisted of 571 patients. The analysis showed that non-squamous patients treated with ALIMTA achieved a statistically higher overall survival compared to those treated with docetaxel (9.3 months and 8.0 months, respectively; hazard ratio 0.778 [95% CI 0.607- 0.997]). Conversely, the analysis suggested that patients with a squamous histology and treated with docetaxel had a statistically higher overall survival compared to those treated with ALIMTA (7.4 months and 6.2 months respectively; hazard ratio 1.563 [95% CI 1.079, 2.264]). Patients with a non- squamous histology represented the majority of the patients on the trial.

The retrospective analysis was driven by preclinical data that suggested patients with a lower expression of thymidylate synthase (TS) enzyme show an increased efficacy when treated with ALIMTA.(3,4) The histological type of NSCLC is determined by how the cancerous cells appear under a microscope. Two of the most common histological types of NSCLC are adenocarcinoma and large cell carcinoma (5) and constitute approximately 55 percent of all NSCLC diagnoses.(6) These two subgroups, a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., PHILADELPHIA,Nov.25/PRNewswire-FirstCall/--ERT(N...ey,theCompany,sPresidentandCEO,andKeithSchneck,the...topresentatthe21stAnnualPiperJaffrayHealthCareConf...York. ,, Interestedpartiesmayaccessthepresentat.../www.ert.com .Thewebcastmayalsobeaccessedat http:/...
(Date:11/25/2009)..., WESTPALMBEACH,Fla.,Nov.25/PRNewswire-FirstCall/-...peciallythe27millionlivingwithuntreated hearinglos...CindyBeyer. ,, Dr.Beyer,seniorvicepresidentofHe...and hearingaids companies,saidstudieshavelinkedhea...hichcaneasilybeintensifiedatholidaygatheringswithf...
(Date:11/25/2009)..., HARBIN,China,Nov.25/PRNewswire-Asia-FirstCall/--...eCompany")(Nasdaq: CSKI ),a,leadingfullyintegrated...he-counterdrugsinthePeople,sRepublicofChina("PRC")...neseNationalInstitutefor,theControlofPharmaceutica...fitsnewproducts:itsDiagnosticKitforHumanProstateSp...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Cats Purrfect at Getting Needs Met Study Shows 51502 1Cats Purrfect at Getting Needs Met Study Shows 51502 2Cats Purrfect at Getting Needs Met Study Shows 51502 3St Jude Virologist Honored by the Royal Society 51499 1St Jude Virologist Honored by the Royal Society 51499 2Larry Fitzgerald Offers Advice for Parents With Struggling Readers 51495 1Larry Fitzgerald Offers Advice for Parents With Struggling Readers 51495 2Larry Fitzgerald Offers Advice for Parents With Struggling Readers 51495 3Larry Fitzgerald Offers Advice for Parents With Struggling Readers 51495 4
...ation Demonstrate Advantages Ov...nd, October 1 Critical,Pharmaceuticals, the Notti..., today announced that the successful completion o...ation of the synthetic human growth,hormone (hGH) ...,concentrations were achieved over an extended per...
...re-FirstCall/ --,Pharmaceutical company Pharmaxis ...rketing application for the mucus clearing agent, ...Goods Administration (TGA) division of,the Austral...horized to,market Bronchitol in Australia for the ...based on a multicentre Phase 3 clinical trial,invo...
Other Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia 2
(Date:11/25/2009)...RONTOandCALGARY,Nov.25/PRNewswire/-SentinelleMedic...ing(MRI)coilsandsoftwareandCalgaryScientificInc.,a...introducedawebversionofAegis(TM)Breast4DAdvancedVi...isthefirsttrulyzero-footprintWebclientbasedmedical...Web(TM)platformallowsforzero-footprintaccess-requi...
(Date:11/25/2009)...NFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQualit...r Spare the Air Alert forThursday,No...logsoranyothersolidfuel,bothindoorsandoutdoors. ,...qualitytomorrow,"saidJackBroadbent,executiveoffice...spectthehealthoftheirneighborsandfellowcommunityme...
(Date:11/25/2009)...ess increase blood pressure? This simple question...ears. New Stress-related gene Modulates High Bloo...ood pressure? This simple question has been the f...research has for the first time established a link...essure response to stress in mice as well as human...
(Date:11/25/2009)...often plagued by neurological symptoms, study find...s) -- Neurological side effects are among the pote...ticular cancer who were treated with cisplatin-bas...tudy included 1,409 Norwegian men treated for unil... took part in a follow-up survey conducted from 19...
(Date:11/25/2009)...E, Mass. -- A cancer vaccine carried into the body...nt is the first to successfully eliminate tumors i...nal Science Translational Medicine . , The new ...sts at Harvard University, uses plastic disks impr... under the skin to reprogram the mammalian immune ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2
...Safety and Discuss Policy Recommendations for Movi...administration,s goal of expanding the availabilit...ty of congressional efforts to fulfill the adminis...orum on the quality and safety issues surrounding ...
...oke rehab patients dictates increase in staff and ...il 16 Saebo, Inc. announced in its first quarter ...ecord year in 2008 and has added staff to accommod...half of 2008 alone, we trained an additional 80 ph...
... to other pathogens , , THURSDAY, April 16... salmonella bacteria to invade cells that line the...destruction, Yale University researchers report. ,...his hijacking of cellular machinery to diversify t...
... pregnancy from the infection, CDC warns, , ...nwide assessment of screening data finds that whil...ydia have risen since 2000, more than 50 percent o...0-07 data reported by commercial and Medicaid heal...
...sk management for the health care industry, launch...s earn a five-star rating from the newly implement...Medicare and Medicaid Services (CMS). The CareRise...taffing patterns , quality measures , , ...
... U.S. guidelines for preventing and treating HIV-a...ed by the National Institutes of Health and the Ce...ation with the HIV Medicine Association of the Inf... Adolescents apply state-of-the-art science and me...
Other Medicine News:Health News:Medical Community Reacts to Obama and Congressional Plans to Approve Generic Forms of Biologic Medicines 2Health News:Medical Community Reacts to Obama and Congressional Plans to Approve Generic Forms of Biologic Medicines 3Health News:Saebo United Kingdom Posts Record 2008; Sees Continued Growth in UK for 2009 2Health News:Less Than Half of Young Women Screened for Chlamydia 2Health News:CareRise Launches Five Star Rating System to Help Nursing Homes Improve Their CMS Ratings 2Health News:US releases updated clinical guidelines for HIV-associated opportunistic infections 2Health News:US releases updated clinical guidelines for HIV-associated opportunistic infections 3
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: